Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGC001 in Chinese Patients With Anterior Wall STEMI Planned for pPCI
NCT07306182Phase 2Recruiting
- Sponsor
- Sungen Biomedical
- Start
- Mar 2026
- Primary completion
- Apr 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of SGC001 in ST-segment elevation myocardial infarction (STEMI), sponsored by Sungen Biomedical. Started Mar 2026; status: recruiting.
02
Drugs
SGC001
03
Conditions
ST-segment elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT07306182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07306182.